RESUMO
A monoclonal antibody (TAb 250) specific to an extracellular epitope of the c-erbB-2 protein (gp185) inhibited the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2 in a dose-dependent manner. Treatment of cells with combinations of cis-diammedichloroplatinum (CDDP) and TAb 250 resulted in a significantly enhanced cytotoxic effect. This synergistic cytotoxicity was apparent over a wide range of antibody concentrations (200 pg/ml-100 micrograms/ml) including concentrations that showed no inhibitory effect alone. TAb 250 did not increase the cytotoxic effect of CDDP in a cell line exhibiting no detectable level of gp185. Athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of gp185 showed a greatly enhanced inhibition of tumor growth when treated with TAb 250 and CDDP compared to treatment with the antibody or CDDP alone. This effect was specific inasmuch as TAb 250 did not enhance the growth-inhibitory effect of CDDP on tumor xenografts which were not expressing gp185.
Assuntos
Anticorpos Monoclonais/farmacologia , Neoplasias da Mama/tratamento farmacológico , Cisplatino/farmacologia , Neoplasias Ovarianas/tratamento farmacológico , Proteínas Proto-Oncogênicas/antagonistas & inibidores , Proto-Oncogenes , Animais , Neoplasias da Mama/patologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Sinergismo Farmacológico , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Neoplasias Ovarianas/patologia , Proteínas Proto-Oncogênicas/imunologia , Proteínas Proto-Oncogênicas/isolamento & purificação , Receptor ErbB-2RESUMO
We conducted a trial of a murine monoclonal antimelanoma antibody-ricin A chain immunotoxin (XOMAZYME-MEL) in 22 patients with metastatic malignant melanoma. The dose of immunotoxin administered ranged from 0.01 mg/kg daily for 5 days to 1 mg/kg daily for 4 days (total dose: 3.2 to 300 mg). Side effects observed in most patients were a transient fall in serum albumin with an associated fall in serum protein, weight gain, and fluid shifts resulting in edema. In addition, patients experienced mild to moderate malaise, fatigue, myalgia, decrease in appetite, and fevers. There was a transient decrease in voltage on electrocardiograms without clinical symptoms, change in serial echocardiograms or elevation of creatine phosphokinase MB isozyme levels. Symptoms consistent with mild allergic reactions were observed in three patients. The side effects were related to the dose of immunotoxin administered and were generally transient and reversible. Encouraging clinical results were observed, even after a single course of a low dose of immunotoxin. In addition, localization of antibody and A chain to sites of metastatic disease was demonstrated by immunoperoxidase staining of biopsy specimens. Additional studies are being conducted to continue the evaluation of safety and efficacy of immunotoxin therapy for malignancy.
Assuntos
Imunotoxinas/uso terapêutico , Melanoma/terapia , Ricina/uso terapêutico , Adulto , Idoso , Anticorpos Monoclonais/uso terapêutico , Anticorpos Antineoplásicos/imunologia , Medula Óssea/efeitos dos fármacos , Feminino , Humanos , Imunotoxinas/efeitos adversos , Masculino , Melanoma/imunologia , Pessoa de Meia-Idade , Metástase Neoplásica , Albumina Sérica/análiseRESUMO
T-strain 960 was passaged through 24 serial 10-fold dilutions in media without added urea and with porcine serum albumin fraction V as the only protein enrichment. The organism, either grown in this manner or passaged an additional three times in medium containing horse serum and 0.1 per cent urea, was inoculated into rabbits. Resultant antisera were tested for activity against T-960 growing in these different media by: (i) growth curve analysis in the presence of antiserum, (ii) metabolic inhibition in the presence or absence of complement (fresh guinea pig serum), (iii) complement-dependent killing curves, (iv) double diffusion in gel (Ouchterlong), and (v) a new visual method for the detection of antigen-antibody reactions on glass slides coated with a thin film of indium metal. Our results indicate that the reactivity of the antisera, as assayed by the above methods, is significantly affected by the composition of the growth medium used for preparation of the antigen. In addition, it was possible to determine that the guinea pig serum-dependent killing of T960 was not affected by the presence of ammonium ion.
Assuntos
Antígenos de Bactérias , Meios de Cultura , Mycoplasma/imunologia , Animais , Reações Antígeno-Anticorpo , Técnicas Bacteriológicas , Bacteriólise , Proteínas do Sistema Complemento , Cobaias/imunologia , Cavalos/imunologia , Soros Imunes , Imunodifusão , Índio , Mycoplasma/crescimento & desenvolvimento , Coelhos/imunologia , Albumina Sérica , Suínos/imunologia , UreiaRESUMO
Human antibody responses to immunotoxin components were evaluated in 21 melanoma patients who were treated with XomaZyme-MEL, a murine monoclonal antimelanoma antibody-ricin A chain conjugate. Twenty of the 21 melanoma patients produced antibodies against ricin A chain, while 15 of 21 produced antibodies reactive with the murine monoclonal antibody component. Both IgM and IgG antibody responses were produced. Immunoglobulin responses were usually detected 1 to 2 weeks following initiation of therapy, with peak levels generally attained 2 to 4 weeks posttherapy. Titers of the anti-ricin A chain antibodies were generally higher than those of the antimurine monoclonal antibodies for the dose range tested. There was no clear correlation between the dose of immunotoxin administered and the antibody titer. By use of a competitive flow cytometry assay, antiidiotype responses were demonstrated in eight of 10 melanoma patients who had antimurine antibodies. Both the kinetics of appearance and the relative titers of the antiidiotype responses generally corresponded to the antimurine responses. The development of antimmunotoxin antibodies can reduce the therapeutic potential of immunotoxins through several mechanisms. The development of antibodies in a significant number of patients suggests that optimally effective, repeated courses of therapy will require some procedure for suppressing or abrogating the response against the immunotoxin.
Assuntos
Anticorpos Monoclonais/imunologia , Imunotoxinas/imunologia , Melanoma/tratamento farmacológico , Ricina/imunologia , Anticorpos Anti-Idiotípicos/biossíntese , Anticorpos Monoclonais/uso terapêutico , Humanos , Imunoglobulina G/biossíntese , Imunoglobulina M/biossíntese , Imunotoxinas/uso terapêutico , Cinética , Melanoma/imunologia , Ricina/uso terapêuticoRESUMO
Nine patients with suspected gram-negative bacterial sepsis were studied to determine the safety, pharmacokinetics, and immunogenicity of XMMEN-0E5, a murine immunoglobulin M monoclonal antibody directed against the core lipid A region of bacterial endotoxin. Antibody was administered by single intravenous infusion of 1 to 4 h duration at doses ranging from 0.1 to 15 mg/kg. Five patients had positive blood cultures for gram-negative bacteria, one patient had Torulopsis septicemia, one patient had gram-negative bacterial meningitis, and two patients were culture negative. No evidence of antibody-mediated toxicity was observed at any dose level. The serum half-life of the antibody was approximately 10 h at doses of 0.1 to 7.5 mg/kg and approximately 18 h at a dose of 15 mg/kg. No apparent difference in clearance of antibody was observed between bacteremic and nonbacteremic patients. Human anti-mouse antibodies were detected in the sera of three evaluable patients that received doses equal to or greater than 2.0 mg/kg but not in patients that received lower doses of antibody. This study demonstrates that XMMEN-0E5 is well tolerated at doses from 0.1 to 15 mg/kg and may be immunogenic at doses of 2.0 mg/kg and above. Controlled trials to establish the efficacy of this antibody in the treatment of gram-negative bacteremia are indicated.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Lipídeo A/imunologia , Sepse/terapia , Adulto , Idoso , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/imunologia , Avaliação de Medicamentos , Feminino , Bactérias Gram-Negativas , Meia-Vida , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Human brain natriuretic peptide (hBNP) has demonstrated favorable hemodynamic effects in patients with congestive heart failure; however, the peptidic nature of this compound has focused clinical testing on protocols involving intravenous delivery. We have studied subcutaneous delivery as an alternative method of administering hBNP. Administration of 30 microgram/kg hBNP by either subcutaneous or intravenous delivery protocols resulted in significant hBNP-immunoreactive material in the plasma with area under the plasma concentration-time curve values of 310 +/- 20 nmolxmins/liter and 187 +/- 47 nmolxmins/liter, respectively. Plasma cyclic GMP, a surrogate marker of activation of the biological receptor for hBNP, was elevated for a longer period of time following subcutaneous delivery compared with intravenous delivery. Subcutaneous delivery of 30 microg/kg hBNP resulted in natriuresis, diuresis and reduced systolic blood pressure in anesthetized normotensive rabbits, effects similar in magnitude yet prolonged in duration compared with those elicited by the same dose of hBNP delivered intravenously. Systolic blood pressure following hBNP treatment remained below base-line values for 50 and 150 min following intravenous and subcutaneous delivery protocols, respectively. These results suggests that subcutaneous delivery of hBNP may be a viable therapeutic alternative to intravenous modes of delivery.
Assuntos
Peptídeo Natriurético Encefálico/farmacocinética , Sequência de Aminoácidos , Animais , Pressão Sanguínea/efeitos dos fármacos , GMP Cíclico/sangue , Humanos , Injeções Subcutâneas , Rim/efeitos dos fármacos , Masculino , Dados de Sequência Molecular , Peptídeo Natriurético Encefálico/administração & dosagem , Peptídeo Natriurético Encefálico/farmacologia , CoelhosRESUMO
The A chain of the toxin ricin has been conjugated by a disulfide bond to a murine monoclonal antibody that recognizes the CD5 (T,p67) antigen present on 95% of peripheral blood T lymphocytes. This immunotoxin was used to treat a patient with severe grade III-IV, steroid-resistant, acute graft-vs-host disease (GvHD) after an allogeneic, human leukocyte antigen-identical bone marrow transplant for acute myelogenous leukemia. Immunotoxin therapy produced a complete clinical response in the skin and gastrointestinal tract. The patient tolerated a 14-day course without symptoms or signs of toxic effects. After two days of therapy, circulating T cells could not be demonstrated by indirect immunofluorescence. After therapy, acute GvHD did not recur. However, seven months after therapy the patient demonstrated mild signs of chronic GvHD that were easily controlled with low-dose immunosuppressive therapy. These findings indicate that an anti-T-cell ricin A chain immunotoxin can be given safely for treatment of acute GvHD and may be an effective therapy for this significant posttransplant complication.